ODD will give 7/10yrs (eu/usa) sales protection after drug approval.
Fast track drug approval will allow the drug to be approved after a phase 1b/2b trial, with the requirement that an expansion trial is undertaken to provide more data. Drug sales allowed early on.
To fast track you need to be addressing rare disease with no SOC.
Rare pediatric disease may allow Breakthrough Drug Designation, which helps expedite the drug development and approval.
But we need the drug hitting arms and the trial underway before any of this happens. Hopefully last half of June for that so the 6 month human dosing aligns with the 9 month tox study.
Once drug approval for DMD is given (hopefully achieved), rolling it out to other indications with the same biomarkers becomes much easier as well. So transition to platform drug is also a real possibility.
- Forums
- ASX - By Stock
- PER
- Sarepta FDA Hearing
Sarepta FDA Hearing, page-62
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.5¢ |
Change
0.004(4.94%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.1¢ | 8.5¢ | 8.1¢ | $46.54K | 563.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 164616 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 100110 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 164616 | 0.081 |
3 | 143000 | 0.080 |
1 | 250000 | 0.079 |
3 | 71500 | 0.078 |
2 | 121300 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 100110 | 1 |
0.087 | 125000 | 1 |
0.089 | 102263 | 2 |
0.090 | 146175 | 1 |
0.091 | 108000 | 1 |
Last trade - 15.55pm 28/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online